Expression of TAU in insulin-secreting cells and its interaction with the calcium-binding protein secretagogin by Maj, Magdalena et al.
25Expression of TAU in insulin-secreting cells and its interaction with
the calcium-binding protein secretagoginMagdalena Maj1, Wolfgang Gartner1,3, Aysegul Ilhan1, Dashurie Neziri1, Johannes Attems2
and Ludwig Wagner1
1Department of Medicine III, Medical University of Vienna, Wa¨hringer Gu¨rtel 18–20, 1090 Vienna, Austria
2Institute for Aging and Health, Newcastle University, Newcastle upon Tyne NE4 5PL, UK
3St Vincent Hospital, 1060 Vienna, Austria
(Correspondence should be addressed to L Wagner; Email: ludwig.wagner@meduniwien.at)AbstractTauopathies have been associated with Alzheimer’s disease
(AD), which frequently manifests together with diabetes
mellitus type 2. Calcium-binding proteins such as the recently
identified secretagogin (SCGN) might exert protective
effects. As pancreatic b-cells and neurons share common
electrophysiological properties, we investigated the appear-
ance of TAU (listed as MAPT in the HUGO and MGI
Databases) protein at the islets of Langerhans and b-cell-
derived cell lines which highly express the neuroendocrine-
specific protein SCGN. Six predominant TAU isoforms
could be identified by immunoblotting, which formed TAU
deposits detectable by immunofluorescence and sarkosyl-
insoluble pellets. Using GST–SCGN pull-down assays, a
calcium-dependent SCGN–TAU interaction was found. In
this line, sucrose density gradient fractionation and differentialJournal of Endocrinology (2010) 205, 25–36
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co-appearance of both proteins. Co-localization of TAU
and SCGN within insulinoma cells and islets of Langerhans
mainly restricted to insulin-positive b-cells was demonstrated
by confocal microscopy. Motivated by these findings, we
looked if SCGN overexpression could exert protective
function on Rin-5F cells, which showed differences in
TAU levels. Testing the vulnerability of Rin-5F clones by
MTT assay, we revealed that high TAU levels going along
with highest TAU aggregates could not be antagonized by
high levels of SCGN protein. Our findings demonstrated for
the first time the association of TAU and the calcium-binding
protein SCGN and support earlier results implicating that
b-cells might represent an extra cerebral site of tauopathy.
Journal of Endocrinology (2010) 205, 25–36Introduction
Tauopathy has been associated with neurodegenerative
diseases, cognitive disorders and, in this context most
importantly, Alzheimer’s disease (AD; Kosik et al. 1986,
Goedert et al. 1988). Therefore, the TAU (listed as MAPT in
the HUGO and MGI Databases) protein has attracted a lot of
interest. TAU is important for microtubule dynamics
(Goedert & Jakes 1990) and axoplasmic transport (LaPointe
et al. 2009). AD is characterized by the occurrence of TAU
deposits and formation of neurofibrillary tangles. In the
protein deposits characterizing neurons of AD, TAU occurs in
hyperphosphorylated (P-TAU) states (Delacourte & Defossez
1986, Grundke-Iqbal et al. 1986, Greenberg & Davies 1990).
P-TAU has been shown to be the key mediator of
neurodegeneration and cognitive impairment (Santacruz
et al. 2005). P-TAU disrupts neuronal microtubules (Alonso
et al. 2001) followed by synaptic pathology and neuronal
apoptosis. One hypothesis for cellular pathology of fibrillary
tangles formation suggests a continuous intracellular hypo-
glycaemic state resulting in decreased O-GlcNAcylation ofTAU and subsequent exposition to kinases leading to
hyperphosphorylation (Dias & Hart 2007). However, till
now, the exact cellular processes finally leading to cytotoxic
effects and influencing factors are still unknown.
Neurons and neuroendocrine cells share several charac-
teristics with respect to protein expression patterns, electro-
physiological properties and pathophysiological processes
(Tischler 2002). Similar to neurodegenerative diseases, b-cells
of individuals suffering from type 2 diabetes are characterized
by accumulation of intracellular islet amyloid peptide (IAPP)
deposits ( Janson et al. 2004, Miklossy et al. 2008). In addition to
IAPP, the presence of P-TAU has been demonstrated recently in
pancreatic islets of individuals suffering from diabetes mellitus
type 2 (Miklossy et al. 1999, 2008, Janson et al. 2004). In
analogy to neurons of the central nervous system (CNS), these
protein deposits seem to exert cytotoxic effects to b-cells
(Lorenzo et al. 1994, O’Brien et al. 1995, Schubert et al. 1995,
Janson et al. 1999). The co-appearance of islet amyloid and
neuritic plaques in the brain highlights the analogy between
AD and type 2 diabetes at the cellular level, which is reflected
by epidemiological studies ( Janson et al. 2004, Ristow 2004).DOI: 10.1677/JOE-09-0341
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excitability, leading via an increase in intracellular calcium
ions to exocytosis. Several calcium-binding proteins have
been shown to be responsible for transmission of these
calcium signals. In light of the functional importance of the
calcium homoeostasis for exocytosis in a pulsatile mode and
its impairment in the course of type 2 diabetes (O’Rahilly
et al. 1988), the involvement of TAU and calcium-binding
proteins in these processes has to be highlighted.
In this respect, the neuroprotective effect of calcium-
binding proteins has to be stressed. Calretinin-immunoreactive
neurons seem to be unaffected in AD, and calbindin seems to
exert neuroprotective effects in ageing neurons (Hof et al.
1993, Greene et al. 2001). Another point in this direction is
the recently described resistance of hippocampal neurons
expressing the calcium-binding protein secretagogin (SCGN)
to neurodegeneration (Attems et al. 2008). The parallel
involvement of calcium-binding proteins and TAU, which is
suggested by these data, was underlined by the recently
described interaction of a novel EF-hand calcium-binding
protein and TAU in the CNS (Vega et al. 2008).
SCGN is a calcium-binding protein with similarities
to calmodulin and calbindin-D28K, which is strongly expressed
in pancreatic b-cells, other neuroendocrine cells and distinct
neurons of the CNS (Wagner et al. 2000, Gartner et al. 2001,
Cras-Meneur et al. 2004, Attems et al. 2007, Rogstam et al.
2007). SCGN was demonstrated to exert effects on secretion
control and transcription processes in b-cells. Based on
these findings and on recent structural analysis, SCGN was
classified rather as calcium sensor than as calcium buffer (Wagner
et al. 2000, Gartner et al. 2007, Rogstam et al. 2007).
To address this subject, we investigated the appearance of
TAU isoforms in b-cells using a rodent insulinoma cell model.
Furthermore, we investigated the biophysical states of TAU
using confocal microscopy, ultracentrifugation and detergent
treatment to reveal its resemblance to tauopathy in AD.
Motivated by the established protective potential of
calcium-binding proteins, we investigated the parallel
expression of neuroendocrine-specific SCGN and TAU in
insulin-secreting cells and tested whether overexpression
could influence features of tauopathy. We additionally
analysed the interaction capacities of both proteins and
present its calcium dependence.Materials and Methods
Antibodies
The polyclonal rabbit anti-human TAU (Cat. no. A 0024) was
purchased from DakoCytomation (Denmark, Glostrup), the
anti-TAU (3-repeat isoform RD3; Cat. no. 05-803) from
Upstate Cell Signaling Solution (Lake Placid, NY, USA), the
anti-human PHF-TAU mAb (clone AT8; Lot. no. FK 93121)
from Pierce (Rockford, IL, USA), the mouse monoclonal
anti-SCGN D24 Ab (Cat. no. MAB5622, Chemicon,Journal of Endocrinology (2010) 205, 25–36Temecula, CA, USA), the mouse monoclonal anti-b-actin
(AC-15; Cat. no. NB600-501) from Novus Biologicals
(Littleton, CO, USA), the monoclonal anti-SNAP-25
(Cat. no. S5187) from Sigma–Aldrich, the monoclonal anti-
a-tubulin (Cat. no. T9026) from Sigma–Aldrich, the
mouse monoclonal anti-rat insulin D3E7 (Cat. no. RDI-
TRK2IP10-D3E7, Research Diagnostics Inc., Flanders, NJ,
USA), the peroxidase-conjugated goat anti-mouse immuno-
globulins (Cat. no. P 0447) and the peroxidase-conjugated
goat anti-rabbit immunoglobulins (Cat. no. P 0448) from
DakoCytomation. The rabbit anti-SCGN antibody was
generated against recombinantly produced SCGN protein as
described in previous work (Wagner et al. 2000, Gartner et al.
2001). The Alexa Fluor 488 F(ab 0)2 fragment of goat anti-
rabbit IgG (Cat. no. A 11070) was obtained from Invitrogen,
TO-PRO from Invitrogen (Cat. no. T-3605), and the goat
anti-mouse tetramethylrhodamine isothiocyanate-labeled
affinity-purified F(ab 0)2 fragment from Accurate Chemical
and Scientific (Westbury, NY, USA).Cell culture conditions
Rin-5F clones were generated according to the method as
described earlier (Wagner et al. 2000). In brief, Rin-5F cells
were transfected with SCGN encoding plasmid (SCGN-
pZeoSV2) and selected using Zeocin (Invitrogen).
Rin-5F and INS-1E cells were cultured in RPMI 1640
medium supplemented with 10% foetal bovine serum, 2 mM
L-glutamine, 100 IU/ml penicillin, 10 mg/ml streptomycin
and 50 mM 2-mercaptoethanol (complete culture medium)
in a humidified atmosphere with 5% CO2 at 37 8C. Cell
cultures were passaged every 3 days using trypsin (0.25%).
In order to mimic diabetic conditions, we used sera from
diabetic patients and non-diabetic individuals. The complete
culture medium was supplemented with 10% of these
human sera, and individual clones were incubated using the
supplemented culture media for 48 h. Rin-5F insulinoma
cell clones were then further processed by FACS analysis for
intracellular TAU staining as described below. In parallel,
mRNA was isolated and tested for TAU transcription using
TaqMan probe-based TAU RT-qPCR as described below.
Additionally, cellular protein was isolated and analysed for
changes in TAU level by immunoblotting as described below.Preparation of cell lysates
After washing the cell monolayer with PBS, cells were scraped
from the culture dish into lysis buffer. The lysis buffer
consisted of Tween 20 substituted (0.1%) PBS (TPBS)
supplemented with the following protease inhibitors: 1 mM
phenylmethylsulphonyl fluoride (PMSF; Sigma; Cat. no.
P-7626) and 10 mg/ml aprotinin (Sigma; Cat. no. A6103).
The resultant lysate was passed once through a 24 G needle
and centrifuged at 13 000 g. The remaining supernatant was
either snap frozen in liquid nitrogen and stored atK80 8C, or
immediately used.www.endocrinology-journals.org
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with PBS and then scraped into 8 M urea containing
1% 2-mercaptoethanol. The cell lysate was centrifuged at
48 000 g for 15 min at 4 8C in order to pellet DNA. The
supernatant was subsequently boiled for 2 min in SDS sample
buffer and loaded onto SDS-PAGE.Immunoblotting
The cell lysate (20 mg) and recombinant protein were loaded
onto SDS-PAGE gels (8 or 12%). Following electrophoretic
separation, proteins were transferred onto nitrocellulose using
a semi-dry blotting device. The membranes were blocked
with 1:10 diluted blocking solution (10% BSA diluent/
blocking solution, Cat. no. 50-61-01, KPL, Gaithersburg,
MD, USA) and were then serially exposed to the primary
antibody (over night at 4 8C) and the detection Ab (HRP-
conjugated goat anti-mouse or goat anti-rabbit; 50 min at
room temperature (RT)). Antigen visualization was per-
formed by chemoluminescence using the Lumi Imager F1
(Roche). Pictures were processed by PhotoShop Version 6.
Signal intensities were densitometrically measured using the
Lumi Analyst 3.1 software and set in relation to the
housekeeping protein.
For phospho-TAU blotting, individual cell clones were
collected and washed in ice-cold RPMI and lysed in
Weinberg cell lysis buffer (50 mM Hepes, 0.5% Nonidet
P-40, 250 mM NaCl, 5 mM EDTA, pH 7.0, 1 mM PMSF,
1 mM sodium orthovanadate, 50 mM b-glycerophosphate).
The cell lysate was kept on ice for 10 min under frequent
tapping and centrifuged at 13 000 g at 4 8C for 10 min.
Lysates of equal cell numbers (1!106 cells) from each clone
were loaded onto SDS-PAGE and transferred onto PVDF
membrane. After the blocking procedure as described above,
blots were developed using AT8 mAb. For loading control,
actin and the pan TAU blotting was used.FACS measurement
After washing the cell monolayer with PBS, cells were
trypsinized. A cell suspension (1!106) from each cell clone
was transferred into FACS tubes (Screen Mates Tubes 1.4 ml,
Cat. no. 4140, Thermo Scientific, Fisher, Vienna, Austria) in
triplicates including a control for each clone. After washing
cells with PBS, cells were fixed using 50 ml fixation solution
(Reagent A, Fix & Perm, Cat. no. GAS-002, Szabo Scandic,
Wien, Austria) for 25 min at RT. Following a PBS washing
step, cells were permeabilized using 50 ml permeabilization
solution (Reagent B, Fix & Perm, Cat. no. GAS-002, An
Der Grub, Vienna, Austria) for 30 min at RT, subsequently
adding 50 ml primary antibody (anti-human TAU Ab,
dilution 1:40) for 40 min. After washing with PBS, cells
were incubated for 50 min with 50 ml secondary antibody
(Alexa 488 goat anti rabbit, dilution 1:300). Following
washing with PBS (3!), FACS measurement was performed
on Beckton Dickinson FacsCanto II. The mean fluorescencewww.endocrinology-journals.orgintensity was recorded in quadruplicate, and results were
calculated as meanGS.D. Each experiment was carried out at
least three times.Quantitative real-time PCR
After pretreatment with DNase I (Invitrogen; 15 min, RT),
1 mg total RNA was subjected to reverse transcription (1 h,
40 8C) using SuperScript II (Invitrogen). The synthesis
reaction was stopped by heating (15 min, 65 8C).
cDNA was diluted 1:6 and used as template together with
TaqMan TAU-specific probe (Applied Biosystems, Foster
City, CA, USA) and 2!MasterMix (Applied Biosystems).
Each sample was measured in duplicate in microtiter Optical
96-well Reaction Plate (Applied Biosystems). The PCR and
data monitoring were carried out at the StepOnePlus Fast
Real-Time PCR System (Applied Biosystems). Expression
values were calculated according to the DDCt method.
As endogenous control, the TaqMan GAPDH probe (Applied
Biosystems) has been used.Subcellular fractionation
Rin-5F cell clones used for disruption and differential
centrifugation were cultured for 2 days. In order to separate
cellular compartments, a method developed by other research
groups (Simpson et al. 1983, Albrektsen et al. 2001) was
applied. After two washes in PBS, the cell monolayer was
scraped into ice-cold PBS and washed once in sucrose
holding buffer (SHB; 20 mM Tris/HCl, pH 7.4, 1 mM
EDTA, 0.25 mM sucrose) containing protease inhibitors
(PMSF and aprotinin). All manipulations were carried out on
ice. Cells were disrupted by pulling the cell suspension three
times through a 24-gauge needle and twice through a
26-gauge needle. Cell nuclei were pelleted by centrifugation
at 10 000 g (10 min). The resultant post-nuclear supernatant
was centrifuged for 20 min at 16 000 g for obtaining a pellet
consisting of mitochondria, peroxisomes (Mit/Per) and
plasma membranes (PM). These were resuspended in 1.5 ml
SHB and overlaid onto a sucrose cushion buffer (1.12 M
sucrose, 1 mM EDTA, 20 mM Tris/HCl, pH 7.4). After
centrifugation at 101 000 g for 25 min, PM were taken from
the interface, resuspended in SHB and centrifuged at 16 000 g
for 15 min for pelleting.
The supernatant obtained after pelleting mitochondria,
peroxisomes and PM were centrifuged at 48 000 g (20 min)
resulting in a pellet of high-density microsomes (HD). This
resultant supernatant underwent centrifugation at 212 000 g
for 70 min toyield a pellet containing low-density microsomes
(LD). The supernatant of this final centrifugation step was
taken as cytosol. Proteins in the pellet were redissolved in 8 M
urea. The protein content was evaluated by Bio-Rad protein
assay. Equal quantity of protein (15 ml) was loaded from each
individual fraction onto an SDS-PAGE, blotted onto
nitrocellulose and developed with anti-human pan-TAU Ab,
anti-SCGN Ab, anti-SNAP-25 mAb and anti-a-tubulin mAb.Journal of Endocrinology (2010) 205, 25–36
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The TAU solubility assay was performed as described recently
(Khlistunova et al. 2006). Briefly, cells were scraped into
10 mM Tris–HCl (pH 7.4) containing 0.8 M NaCl, 1 mM
EGTA and 10% sucrose. The resultant homogenate was spun
for 20 min at 20 000 g. Subsequently, the pellet was
re-homogenized and re-centrifuged at 20 000 g. Supernatants
were combined and incubated for 1 h at 37 8C in the presence
of 1% of N-laurylsarcosinate. After a final centrifugation at
100 000 g for 1 h, the sarkosyl-insoluble pellet was dissolved
in SDS-sample buffer containing 1.5% 2-mercaptoethanol
and was analysed by SDS-PAGE.Immunofluorescence
Cytospin preparations of insulinoma cell culture cells as well
as cryosections of pancreatic tissue (obtained from pancreatic
tumour resection) were air dried and stained as described
below or stored at K20 8C wrapped in aluminium foil.
Tumour tissue was obtained within a programme approved by
the ethical committee of the Medical University of Vienna.
For immunostaining, frozen slides were brought to RT
before unwrapping. Tissue sections were fixed in acetone,
blocked with 100 ml RPMI 1640 medium containing 10%
FCS followed by an incubation (4 h, RTor over night at 4 8C)
with the following primary antibodies: the polyclonal rabbit
anti-human TAU antibody, diluted 1:200 in PBS; or with the
polyclonal, affinity purified rabbit anti-SCGN antibody,
diluted 1:400 in PBS. For dual immunofluorescence, the
rabbit polyclonal anti-human TAU Ab and the monoclonal
mouse anti-SCGN mAb (clone D24, Millipore) were used as
primary antibodies. As secondary antibodies, either the goat
anti-mouse TRITC (diluted 1:200) or the goat anti-rabbit
Alexa 488 (diluted 1:200) Abs were used (2 h). In dual colour
analysis, both detection antibodies were used in parallel. For
visualization of the nuclei, slides were counterstained with
TO-PRO. Finally, the slides were mounted with Vectashield
(Vector Laboratories, Burlingame, CA, USA). All incubations
were performed in a moist chamber at room temperature.
Between each incubation step, the slides were repeatedly
washed for 10 min in PBS. Antigen visualization was
performed using an Aristoplan fluorescence microscope
(Leitz, Labortwert FS, Germany) or the Axiovert confocal
microscope 200 M (Zeiss, Jena, Germany). The images were
processed using LSM 5 software (Zeiss).Generation of the human SCGN–GST recombinant
fusion protein
The coding region of the SCGN gene was cloned into the
GST expression vector pGEX-1lT (Healthcare Biosciences,
Sweden, Uppsala) as described earlier (Wagner et al. 2000).
For protein production, the SCGN–GST encoding
pGEX-1lT was expressed in Escherichia coli BL-21
according to the manufacture’s instructions. ProteinJournal of Endocrinology (2010) 205, 25–36purification was performed using Glutathione Sepharose 4B
(17-0756-01, Healthcare Biosciences). The GST fusion
protein was liberated from the washed beads (PBS buffer)
by thrombin cleavage.
Pull-down assay
GST–SCGN full-length or, for control, GST without fusion
protein-loaded beads were incubated in precleared insuli-
noma cell lysate using non-denaturing lysis conditions
(as described above) at 4 8C under constant rotation for 1 h.
After washing insulinoma cell lysate exposed beads, the
bound protein was eluted by using EDTA (10 mM)
containing washing buffer (TPBS). For subsequent analysis,
the resultant protein eluate was boiled for 3 min and loaded
onto SDS-PAGE. The gel was further processed as described
in the immunoblotting section.
MTT assay
Equal numbers (2!105) of each cell clone were transferred
into a 48-multiwell plate and incubated with complete
medium or with 0.1% BSA containing RPMI 1640 for
24 h. Following this incubation period, the culture medium
was removed and replaced with RPMI containing MTT
(3-(4,5-dimethylthiazol-2-yl) 2,5-diphenytetrazoliumbromid);
500 mg/ml). Cells were incubated for 60 min, and after
removal of supernatant, the resultant formazan dye was
dissolved in HCl acidified (50 mM) dimethyl sulphoxide
(DMSO) containing SDS (10% w/v). After a short incubation
period (2 min), the colour intensity was evaluated by
spectrophotometric measurement. Each experiment was
carried out in tetraplicate and repeated at least three times
on individual days.Results
Co-expression of TAU and SCGN in b-cells and insulinoma cells
In order to answer the question of TAU presence in b-cells,
we stained pancreatic tissue by dual colour fluorescence and
demonstrated TAU-positive cells to co-localize with insulin-
positive b-cells at the islets of Langerhans (Supplementary
Figure 1, see section on supplementary data given at the end
of this article). A negative control for TAU staining is
included in the lower panel.
To evaluate the co-localization of TAU and SCGN,
confocal immunofluorescence of islets of Langerhans
(Fig. 1A, upper panel) and of human insulinoma cytospin
preparations (Fig. 1A, lower panel) as well as of Rin-5F
cytospin preparations was performed. This revealed consider-
able expression of TAU (green) in normal b-cells as well as in
insulinoma cells (Fig. 1A). Expectedly, SCGN expression
(red) was abundantly found in islet cells as well as in
insulinoma cells (Fig. 1A). Using dual-colour visualization
of individual antigens (TAU, green; SCGN, red), we foundwww.endocrinology-journals.org
Figure 1 TAU immunofluorescene of pancreas, insulinomas and of the rat
insulinoma cell line Rin-5F. (A) In pancreas (upper panel) and in insulinomas
(lower panel), pan-TAU immunofluorescence staining revealed considerable TAU
(green) expression. Co-immunostaining with SCGN a protein specific for islets of
Langerhans (red) demonstrated co-localization of TAU and SCGN (yellow) within the
individual cells. For nuclear staining, TO-PRO (blue) was used. Antigen visualization
was performed by confocal microscopy (scale bar: upper panel 30 mm, lower panel
15 mm). (B) Using the pan-TAU Ab, we demonstrated strong TAU (green) expression
in the rat insulinoma cell line Rin-5F and show cytoplasmic TAU aggregates (arrows)
in clone 1 (upper panel). Dual-colour staining for TAU (green) and a-tubulin (red)
demonstrates co-localization of both proteins to some degree (yellow coloration)
within individual cells (upper and middle panel). For nuclear staining, TO-PRO (blue)
was used. The lower panel demonstrates negative control for TAU staining using
preimmune serum. Signal visualization was performed by confocal microscopy.
TAU appearance in b-cell lines . M MAJ and others 29
www.endocrinology-journals.org Journal of Endocrinology (2010) 205, 25–36
M MAJ and others . TAU appearance in b-cell lines30a considerable extent of co-localization of both proteins
(yellow) within the tested tissues (Fig. 1A). For nuclear
staining, TO-PRO (blue) was used.
Interestingly, in Rin-5F cells, we detected occurrence of
TAU deposits (arrow), which ranged from 5 to 8% in clone 1
(Fig. 1B, upper panel) to 1–2% in the other clones. To
visualize the tubular distribution of TAU, we performed dual-
colour confocal microscopy for TAU (green) versus a-tubulin
(red) using clone 4. This demonstrated that in some areasJournal of Endocrinology (2010) 205, 25–36(centrosomes) TAU and tubulin co-localize (yellow color-
ation; Fig. 1B, middle panel). TAU negative control staining is
demonstrated in the lower panel of Fig. 1B.Expression of TAU isoforms in rat insulinoma cell lines
To investigate the presence of TAU isoforms in insulinoma
cells, TAU immunoblotting was performed. Immunoblotting
results confirm expression of TAU in rat insulinoma cells Rin-
5F and INS-1E (Fig. 2A). As a CNS-derived reference,
cerebral cortex was included. This comparison intended to
establish whether similar TAU isoforms occur in the CNS and
pancreatic b-cells. Whereas in Rin-5F cells and INS-1E
insulinoma cells, a comparable isoform pattern could be
documented (Fig. 2A), and the two larger TAU variants seen in
insulinomas were almost absent in CNS derived tissue lysate. In
contrast, smaller variants known for CNS were much less
abundant in insulinoma cell lysates. Nonetheless, TAU
expression quantities in insulinoma cells did not reach the
amount seen in the cerebral cortex.
Based on the co-expression of TAU and SCGN in
insulinoma cells, we were interested if the expression extent
of both proteins was correlated. For that purpose, the
expression intensity of TAU was analysed in several Rin-5F
clones characterized by different extents of SCGN expression.
This revealed that the highest SCGN overexpression (clone 1)
was paralleled by the highest TAU abundance (Fig. 2B). The
other clones showed varying TAU and SCGN expression
intensities. Notably, considerable amount of TAU was also
present in the SCGN sham-transfectant clone 3 used as a
control (Fig. 2B, lane 3). All clones expressed endogenous rat
SCGN. TAU blots were densitometrically analysed, and TAU
levels were set in relation to the housekeeping protein b-actin.
In order to evaluate the level of TAU phosphorylation, we
performed P-TAU immunoblotting of the same cell clones
and demonstrated high level of phosphorylation within all
testes clones (Fig. 2B, lower panel). Note that for P-TAUFigure 2 Expression of TAU isoforms in rat insulinoma cell lines.
(A) Immunoblot analysis of INS-1E cells (lane 2) and of Rin-5F cells
(lane 3) revealed strong TAU expression in the rat insulinoma cell
lines. As reference, cerebral cortex (lane 1) was included.
To confirm comparable protein loading, actin immunoblotting
is presented in the lower panel. (B) To compare endogenous and
recombinant SCGN (r-SCGN) level with TAU protein level,
immunoblotting of Rin-5F cell clones, clone 3 representing control
(lane 1–4), using pan-TAU and SCGN-specific Abs was performed.
Varying TAU and SCGN expression levels were detected. Actin was
chosen as reference protein. P-TAU immunoblotting is demon-
strated at the lower panel. Depicted is one representative figure out
of three. For quantification, densitometric scanning was performed
(right side of the corresponding blot). (C) Sarkosyl solubility of TAU
in Rin-5F cells was determined by TAU solubility assay. This
revealed the presence of sarkosyl-soluble (upper panel) and
sarkosyl-insoluble TAU variants (lower panel, one representative
experiment out of three is demonstrated). In parallel, SCGN was
also found in both the pellet and the supernatant. The graph depicts
the results of densitometric scanning (meanGS.D.) of three
individually experiments performed on different days.
www.endocrinology-journals.org
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applied, which resulted in different banding pattern.
Independent of its isoforms, TAU occurs as sarkosyl-insoluble
pellet especially in neurons of AD patients. To test Rin-5F
cells for the presence of sarkosyl-insoluble TAU aggregates, a
TAU solubility assay was performed. Expectedly, TAU was
found in the sarkosyl-soluble fractions but also to a high amount
in the sarkosyl-insoluble pellet (Fig. 2C). SCGN showed
similar characteristics with respect to sarkosyl solubility. Clone 1,
which was characterized by the highest SCGN expression,
exhibited the highest amount of insoluble TAU aggregates.
Individual clones were tested for P-TAU by immuno-
fluorescence. Highest P-TAU staining intensities were found
in clone 1 followed by clone 4 (Fig. 3). In line with earlier
studies performed on neuroblastoma cell lines, the immuno-
fluorescence results demonstrated the presence of P-TAU in
the cytoplasm but even to a stronger extent within the cell
nucleus. In the cytosol, P-TAU exhibited a granular staining
pattern. The nuclear presence was confirmed by subcellular
fractionation as described further down.Rin-5F cells under type 2 diabetic conditions
In order to investigate the influence of sera derived from
patients suffering from diabetes mellitus type 2 on changes in
TAU expression levels and isoform processing in Rin-5F
cells, FACS analysis in parallel with RT-qPCR and western
blotting of Rin-5F cells incubated with these sera was
performed. We detected changes by FACS and RT-qPCR
(increases); however, these did not reach the level of
significance. In addition, we observed changes in cell
morphology and growth pattern of insulinoma cell clones.
In order to follow these findings, the influence of these
conditions on TAU deposit formation was investigated by
immunofluorescence microscopy. However, also in this
direction, no significant difference could be observed.Intracellular distribution pattern of TAU in Rin-5F cells
Subcellular fractionation on a sucrose gradient
To identify the intracellular TAU containing compartment
and co-localized proteins, sucrose gradient fractionation of
Rin-5F cells, and subsequent immunoblotting for pan-TAU,Figure 3 The presence of phospho-TAU in Rin-5F c
intracellular P-TAU, we performed immunofluorescence
the presence of P-TAU in each of the clones (scale bar:
www.endocrinology-journals.orga-TAU, a-tubulin, SNAP-25 and SCGN was performed
(Fig. 4A). This revealed the presence of pan-TAU in all
fractions with highest abundance in fractions 12–15,
representing cytosolic compartments. Interestingly, P-TAU
was also found in higher sucrose densities (w1–1.3 M)
representative for membranous fractions and high molecular
weight aggregates as well as at lower densities representative
for cytosolic fractions (w0.4–0.3 M). Expectedly, a-tubulin
was found to co-localize with cytosolic pan-TAU, whereas
SNAP-25, a well-known member of the SNARE complex
and marker for membranous cellular compartments, was
found to co-localize with membrane-associated TAU or
TAU aggregates. Co-appearance of SCGN/TAU was found
in high sucrose densities as well as in cytosolic fractions
(low densities).
Subcellular fractionation by ultracentrifugation To
investigate these findings in more detail, ultracentrifugation
of disrupted Rin-5F cells was performed. This resulted in
the differentiation of six cellular compartments: LD, HD,
Mit/Per, cytosol, nuclei and PM. The presence of TAU and
SCGN was demonstrated by immunoblot analysis of the
individual fractions (Fig. 4B). Interestingly, TAU protein was
pelleted in the LD and HD fraction including degradation
products, and was absent in cytosol. In cell nuclei, TAU
protein was found at high quantity confirming immuno-
fluorescence data. TAU within the nuclear fraction showed
no degradation products. Consistent with sucrose gradient
data, SCGN was also pelleted together with TAU in the LD
and HD, and it was also found in high quantity in cytosol.
Tubulin was detected in LD, cytosol and at lower quantity
within the nuclei.TAU associated with SCGN in Rin-5F cells
It has been shown that pyramidal neurons at the hippocampus
expressing SCGN are greatly free of hyperphosphorylated TAU
deposits (Attems et al. 2008), and TAU was shown to interact
with other members of the EF-hand calcium-binding protein
family in mouse brain (Vega et al. 2008). The calcium-binding
protein SCGN has been demonstrated to be highly and
specifically expressed within the islets of Langerhans (Wagner
et al. 2000, Cras-Meneur et al. 2004). Therefore, TAU/SCGNells using AT8 mAb. To test for the presence of
microscopy of various Rin-5F clones. This revealed
10 mm).
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Figure 4 Intracellular TAU distribution pattern in Rin-5F cells. (A) Sucrose gradient
fractionation. To analyse the intracellular TAU distribution, Rin-5F cell lysate was subjected
to sucrose gradient fractionation and subsequent immunoblotting of the individual fractions.
TAU isoforms (pan-TAU) as well as phosphorylated TAU (P-TAU) were found in the
membranous as well as in the cytosolic fractions, with highest abundance of TAU in the
cytosolic fractions. SNAP-25 immunoblotting was included to confirm the membranous
compartments; a-tubulin was included to confirm cytosplasmic compartments. In analogy to
our immunofluorescence data, TAU was found to co-appear with SCGN. (B) Differential
ultracentrifugation. TAU variants and degradation products resided in the low density
microsomes (LD) and at lower quantity in the high density microsomes (HD). In addition,
nuclear TAU, which had only marginal degradation products, was recovered. SCGN was
detected in LD, HD, cytosol and nucleus. a-Tubulin was detected in LD, cytosol, nucleus and
in scant quantity in HD. SNAP-25 appeared at highest quantity in mitochondria/peroxisomes
and nucleus as well as in LD, HD and PM.
M MAJ and others . TAU appearance in b-cell lines32interaction seemed plausible in neuroendocrine cells. For
this purpose, the recombinant SCGN has been engineered as
a GST fusion protein (Fig. 5A, upper panel, lane 1) and as a
control GST alone was used (Fig. 5A, upper panel, lane2).
The GST–SCGN beads were incubated with insulinoma cell
lysate in parallel with GST only and after washing, the eluted
proteins were loaded onto SDS-PAGE gels and blotted for the
presence of TAU association. A single TAU-specific band could
be observed at a molecular size of about 60 kDa (Fig. 5A, lower
panel, lane 1). No TAU binding was present in GST-loaded
beads (Fig. 5A, lower panel, lane 2).Journal of Endocrinology (2010) 205, 25–36The striking observation that one single TAU isoform was
interacting with SCGN led to ask a question whether this
represents a 3R or 4R TAU isoform. Following this idea, we
first developed the pull-down assay with a 3R TAU isoform-
specific mAb. This did not reveal any signal. In contrast, the
pan-TAU-specific Ab detected the interacting TAU isoform
(Fig. 5B, lane 3), suggesting that the SCGN-interacting TAU
variant represents a 4R TAU. As a member of the EF-hand
calcium-binding protein family, the functions of SCGN are
mainly calcium dependent. To clarify if the TAU–SCGN
interaction is calcium dependent, we included EDTA atwww.endocrinology-journals.org
Figure 5 Recombinant SCGN and TAU interaction. The recombi-
nant fusion protein GST–SCGN was loaded onto gluthathione–
sepharose beads (upper panel, lane 1) and as control GST alone
(upper panel, lane 2). Both variants were incubated in Rin-5F cell
lysate, and bound protein was eluted from its binding partner after
washing off non-specific interacting proteins. The eluate was loaded
onto SDS-PAGE, blotted onto nitrocellulose and developed for the
presence of TAU using a pan-TAU-specific antibody (lower panel,
lane 1 derived from GST–SCGN; lane 2 derived from GST alone).
(B) Gluthathione–sepharose beads loaded with GST–SCGN were
exposed to Rin-5F cell lysate in the absence (lane 2, 3) and in the
presence of 5 mM EDTA (lane 4). The eluate of washed beads was
loaded on SDS-PAGE, blotted onto nitrocellulose and developed
for 3R TAU variants (lane 2) or for pan-TAU (lane 1, 3, 4). Cell lysate
input (lane 1).
Figure 6 MTT assay for Rin-5F clones. MTT assay upon exposure of
Rin-5F clones to low protein concentration (stress condition) for
24 h compared with complete culture medium. The highest effect
on apoptosis and growth inhibition was observed in clone 1
(K0.30G0.06 colourimetric units), which was compared to
clones 2 (K0.10G0.03 colourimetric units; P!0.0007), clone
3 – control (K0.16G0.02 colourimetric units; P!0.004) and
clone 4 (K0.08G0.02 colourimetric units; P!0.0003).
TAU appearance in b-cell lines . M MAJ and others 33various concentrations in the cell extract/binding buffer. This
clearly eliminated SCGN and TAU interaction even at the
lowest tested EDTA concentrations (2.5 mM), indicating the
importance of calcium for the TAU–SCGN interaction
(Fig. 5B, lane 4).Comparative MTT assay in Rin-5F clones
Calcium-binding proteins are known to exert cell protective
effects whereas high TAU levels are observed in neuro-
degenerative disorders. For that reason, we evaluated by MTT
assay whether Rin-5F clones exhibiting different SCGN and
TAU expression intensities vary in their susceptibility to
stress-induced cell death and changes in proliferation.
Clone 1, which was characterized by the highest amounts
of TAU levels and the presence of TAU aggregates (see
Fig. 1B, upper panel), is the most sensitive to stress conditions
when compared to clone 2 (*P!0.0001), clone 3 – control
(*P!0.004) and clone 4 (*P!0.0001; Fig. 6). Demonstrated
is the meanGS.D. of quadruplicate samples of one representa-
tive experiment out of three.www.endocrinology-journals.orgDiscussion
Neurodegenerative diseases and the progressive loss of b-cell
function occurring in the course of diabetes mellitus type 2
share pathophysiological characteristics. Moreover, neurons
and neuroendocrine b-cells share several physiological proper-
ties, especially with respect to secretory processes. In b-cells,
little is known about the expression of TAU, a key mediator
of neurodegeneration with potential involvement in secretion.
In this study, we demonstrated the expression of TAU
and its isoforms in pancreatic b-cells, in insulinoma tissue
as well as in the rat insulinoma cell lines Rin-5F and INS-1E.
An interesting issue regarding protection against neurode-
generation is EF-hand calcium-binding protein, which exerts
positive effects (Hof et al. 1993, Greene et al. 2001). The
importance of calcium-binding proteins for TAU dynamics in
the CNS was highlighted by Vega et al. (2008). In this respect,
it is important to state that the hexa EF-hand calcium-binding
protein SCGN is highly and specifically expressed in
pancreatic b-cells and insulinomas (Wagner et al. 2000,
Cras-Meneur et al. 2004). Important in this direction was the
observation that pyramidal neurons in the hippocampus
expressing SCGN are devoid of hyperphosphorylated TAU.
This motivated us to study whether SCGN and TAU can
interact in insulinoma cells and might fulfil a similar task at
neuroendocrine sites. Thereby, we conducted pull-down
assays and demonstrated a calcium-dependent interaction of
one TAU isoform with SCGN. Following this observation,
we looked at SCGN overexpressing Rin-5F clones whether
this protein might influence the biophysical state of TAU and
b-cell degenerative effects. This was tested by the prolifer-
ation/apoptosis sensitive MTT assay. Higher extent of SCGN
overexpression did not provide neuroprotection when TAU
aggregates were present. About moderate SCGN over-
expression, no clear conclusion could be reached within the
border of this study. A higher number of clones have to be
tested in further investigations.Journal of Endocrinology (2010) 205, 25–36
M MAJ and others . TAU appearance in b-cell lines34We demonstrated high expression levels of various TAU
isoforms in rodent insulinoma cells. The morphological
appearance of TAU in the cytoplasm of insulin-secreting cells
and its comparison with a-tubulin in dual-colour confocal
microscopy support the assumption that microtubule
dynamics and TAU are of similar importance in the secretory
process of neurons (Goedert & Jakes 1990) and neuroendo-
crine cells via influencing the axoplasmic transport (LaPointe
et al. 2009). For the first time, we elucidated TAU isoform size
pattern in b-cell-derived cell lines. Two larger size variants are
absent in the CNS when comparing b-cell-derived isoforms
with that of mammalian brain. Size variants different from
CNS have been described in peripheral neurons (Taleghany &
Oblinger 1992, Boyne et al. 1995) earlier.
Furthermore, we showed in this study that TAU aggregates
can be found in insulinomas and insulinoma cell lines by
means of cytoplasmic deposits as well as in terms of smears by
size fractionation in SDS-PAGE followed by TAU-specific
immunoblots. In diabetes mellitus type 2, it has already been
shown by immunohistological studies that P-TAU can be
seen in islets (Miklossy et al. 1999, 2008, Janson et al. 2004).
We showed in addition by phosphoblotting, density gradient
sedimentation, and sarkosylate treatment of cell lysate that
aggregates can be found at various quantities depending on
the selected Rin-5F clone.
Protein phosphorylation is tightly regulated in pancreatic
b-cells by intracellular calcium fluctuations. Each peak of
insulin secretion is preceded by an intracellular calcium spike
(Gilon et al. 1993). This rise in calcium is necessary for the
activation of motor proteins and granule expulsion. SCGN
represents an important calcium sensor protein (Rogstam
et al. 2007) in b-cells and might therefore be a candidate for
signal transduction.
SCGN has been shown to have a specific expression
pattern (Wagner et al. 2000, Gartner et al. 2001, Birkenkamp-
Demtroder et al. 2005, Lai et al. 2006, Attems et al. 2007).
Especially, the islets of Langerhans are known for highest
levels of SCGN expression (Cras-Meneur et al. 2004). The
co-expression of SCGN and TAU in Rin-5F cells with
overlapping intracellular distribution implicated association of
both proteins, which was confirmed by pull-down assays.
Interestingly, our results showed that the association of SCGN
is restricted to the 4R isoform. This variant seems to play an
important role in neurodegeneration (Probst et al. 2000).
We demonstrated that the calcium-binding protein SCGN
interacts with this TAU isoform in a calcium-dependent
mode, which might point towards its contribution to the fine
tuning of tubule dynamics with impact on insulin secretion.
To investigate whether similar features of tauopathy such as
in AD brains might occur in insulin-secreting cells, we
screened these cells for the presence of P-TAU and sarkosyl-
insoluble TAU aggregates. Indeed, we found a considerable
amount of P-TAU and sarkosyl-insoluble TAU in Rin-5F
cells. Using disrupted Rin-5F cells, we performed sucrose
density gradient centrifugation and demonstrated that TAU
co-distributes with tubulin and SCGN in cytosolic fractionsJournal of Endocrinology (2010) 205, 25–36ofw0.3 M. However, at higher densities, TAU was detected
in the absence of tubulin. TAU found in w0.8 M sucrose
fractions might represent aggregates, which is supported by
TAU appearance in LD and HD using differential ultra-
centrifugation. This finding has some resemblance to AD
brain lysate sucrose fractionation, where much of TAU was
found in heavy membrane fractions together with the
membrane marker SNAP-25 (personal observation).
Possibly TAU aggregates detected in high-density sucrose
fractions of Rin-5F cells are in line with the observation that
insulinoma cell lines contain sarkosyl-insoluble TAU. To
further confirm this assumption, the sarkosyl-insoluble pellet
was dissolved in SDS buffer and then layered onto the same
sucrose gradient similarly as described by previous authors
(Ksiezak-Reding et al. 1994). This revealed that some of the
TAU protein could not be dissolved in SDS into light
molecules such as it was seen for SCGN. SCGN equivocally
appeared in the light fractions after SDS treatment (M Maj,
W Gartner, A Ilhan, D Neziri, J Attems, LWagner, unpublished
observation). The co-appearance of TAU and SCGN in the
sarkosyl-insoluble pellet suggests aggregation of SCGN
probably together with TAU but this is not irreversible such as
it can be seen for TAU. In this respect, it is plausible to speculate
that certain TAU mutations which are known to trigger
tauopathies (Goedert & Spillantini 2006) have impact on b-cell
function via impaired microtubule dynamics (Levy et al. 2005).
In analogy to the neurons in AD, increased deposits of TAU
and b-amyloid are found in b-cells of patients suffering from
diabetes mellitus type 2 (Miklossy et al. 2008). In order to
evaluate the impact of diabetic conditions on TAU expression,
we exposed Rin-5F cells to sera obtained from diabetic
patients. This resulted in a marginally increased TAU
expression. At this point, it has to be stressed that the
manifestation of diabetes mellitus type 2 is preceded by several
years of hyperinsulinaemia and prediabetic states. Thus, the
trend towards an increased expression of TAU in Rin-5F cells
exposed to serum obtained from diabetic patients, despite the
lack of statistical significance, might be of biological relevance.
In summary, we described the presence of six TAU isoforms
in insulin-producing cells. Furthermore, we showed TAU
protein appearance in hyperphosphorylated states as well as in
protein deposits and as sarkosyl-insoluble aggregates, which all
are resembling features of tauopathy in AD. Additionally, we
demonstrated co-expression and association of one
TAU isoform and the calcium-binding protein SCGN in
insulin-secreting cells. Owing to the bivalent intracellular
functions of TAU proteins and the calcium dependency of the
TAU–SCGN interaction, it seems plausible that these findings
have an impact on the physiology of insulin secretion as well as
on pathological processes leading to b-cell destruction.Supplementary data
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